Search
for

    Research

    5 / 1000+ results

    Community Join

    5 / 447 results

      community Clascoterone - what we have right now

       24 upvotes 7 months ago
      Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

      community Anyone tried Anagen “Smooth Release” oral minoxidil?

       9 upvotes 1 week ago
      People are discussing Anagen's "Smooth Release" oral minoxidil, with some users reporting no side effects or hair growth yet. There are concerns about a potential lawsuit with Veradermics over intellectual property, but no confirmed legal action has been found.

      community Be careful about using non-PG based alternatives of Minoxidil (mathematically speaking, haven’t seen much practical studies)

      in Research/Science  7 upvotes 1 month ago
      Minoxidil formulations often use propylene glycol (PG) for stability and effectiveness, but PG-free alternatives like foams and PEG-based solutions can also be effective with less irritation. Concerns exist about the quality of PG-free minoxidil from lesser-known brands, especially from India, due to potential manufacturing issues.

      community I was wrong about Dutastride. Let the I told you so comments rain in.

       76 upvotes 11 months ago
      Switching from dutasteride to finasteride caused increased hair loss, dandruff, depression, and erectile dysfunction. The user plans to return to dutasteride, possibly with minoxidil, and is considering dosing strategies to manage side effects and regrowth.

      community PP405 is nothing but a scam and Pelage know it.

      in Chat  78 upvotes 1 year ago
      PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

    Learn

    1 / 800 results

      learn KX-826

      • Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical and is not approved as a medicine anywhere. Its first China Phase III trial did not beat placebo; the company reported in March 2026 that a later Phase III of a 1.0% formulation met its primary endpoint, but these results are company announcements, not peer-reviewed, and long-term safety is unknown.